

Daily evidence digest

26 March 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Asymptomatic COVID-19, vaccines in immunosuppressed patients, dynamics of antibody responses, communities of practice

Peer reviewed journals featured:

- Systematic reviews on:
 - Asymptomatic COVID-19 cases [here](#)
 - Dental periodontal procedures and COVID-19 [here](#)
- A scoping review on the indirect impacts of COVID-19 on healthcare delivery, utilisation, and outcomes [here](#)
- Observational studies on:
 - The efficacy and safety of mRNA vaccines in immunosuppressed patients [here](#)
 - The dynamics of SARS-CoV-2 neutralising antibody responses [here](#)
 - The non-validity of self-reported COVID-19 hygiene behaviours [here](#)
 - Time to clinical improvement with and without remdesivir treatment [here](#)
 - COVID-19 end-of-life care in an Australian hospital [here](#)
- A case series on COVID-19-associated mould infection in critically ill patients, in Chile [here](#)
- Commentary on:
 - Convalescent plasma from people vaccinated after COVID-19 infection [here](#)
 - Collective moral resilience in communities of practice during COVID-19 and beyond [here](#)

Letters and correspondence discussed:

- The WHO International Standard for anti-SARS-CoV-2 immunoglobulin [here](#)
- Risk of fomite-mediated transmission of SARS-CoV-2 in child care, schools, nursing homes, and offices [here](#)
- Correspondence regarding a previously published article on neuroimmune interactions and COVID-19 in lung transplant recipients [here](#) and the authors' response [here](#)

Pre-peer review articles featured:

- B.1.526 SARS-CoV-2 (New York) variant neutralised by vaccine-elicited and monoclonal antibodies [here](#)
- Weak humoral immune reactivity in residents of long-term care facilities after one dose of BNT162b2 (Pfizer) vaccine [here](#)
- Serious adverse events following COVID-19 vaccination [here](#)
- Lessons from the UK's COVID-19 vaccination strategy [here](#)
- Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose [here](#)
- Self-reported smell and taste recovery in COVID-19 patients [here](#)
- Characterising post-acute COVID-19 syndrome more than 6 months after acute infection [here](#)

Guidance and reports

- The Australian Institute of Health and Welfare released a new report on cancer screening and COVID-19 in Australia [here](#)
- The Australian Therapeutic Goods Administration (TGA) released its COVID-19 vaccine weekly safety report [here](#)
- The Australian COVID-19 National Incident Room Surveillance Team published its latest epidemiology report [here](#)
- The Australian Technical Advisory Group Immunisation (ATAGI) statement for health care providers on suitability of COVID-19 vaccination in people with history of clotting conditions [here](#)

News and blogs

- COVID-19 viruses are mixing in infected people's cells [here](#)
- The UK Health Security Agency is preparing and protecting from future pandemics [here](#)
- Reflection and lessons needed to be learned to prevent another COVID-19 wave in Portugal [here](#)
- How the US failed to prioritise SARS-CoV-2 variant surveillance [here](#)
- What scientists do and don't know about the Oxford–AstraZeneca COVID-19 vaccine [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern.